2021-2022 Impact Report
Cystic Fibrosis Canada’s 2022 Impact Report Highlights A Year Like No Other
Progress made possible through dedication of donors and supporters
Cystic Fibrosis Canada is pleased to share the 2021-2022 Impact Report, highlighting the progress that was made possible thanks to our donors and supporters.
In this report we celebrate the inspiring stories of people in Canada impacted by cystic fibrosis (CF) and reflect on our work over the past year, including the approval of Trikafta for those aged 12+, one of the fastest rollouts for a CF drug in Canada.
You’ll also read about how Canadians living with CF are getting access to medications through our clinical trial network, the impact of the Canadian Cystic Fibrosis Registry, how we leveraged partnerships to double the impact of our donor dollars and how our inspiring community and donors continue to go further.
The work last year would not be possible without the support of our incredible community, including people impacted by cystic fibrosis, volunteers, donors, sponsors, clinicians, partners and more. Your contributions are changing lives.
You can read the report here.
